Literature DB >> 22150345

Persistent fasting hyperglycaemia is more predictive of type 2 diabetes than transient fasting hyperglycaemia.

K Inoue1, M Inoue, M Matsumoto, K Akimoto.   

Abstract

AIMS: We investigated the value of persistent fasting hyperglycaemia as assessed by repeated elevated fasting plasma glucose in predicting the progression to diabetes.
METHODS: A retrospective cohort study was conducted from 1998 to 2006 inclusive among 7929 persons (37,742 person-years), with a mean age of 53.0 years at baseline. The cumulative incidence of diabetes was measured. A baseline and follow-up fasting plasma glucose were categorized as normal fasting glucose (< 5.56 mmol/l), or impaired fasting glucose (5.56-6.94 mmol/l).
RESULTS: The cumulative incidence and incidence density of diabetes were 3.5% (275 cases) and 7.3 per 1000 person-years over a mean follow-up period of 4.8 years. The cumulative incidence of diabetes among subjects with impaired fasting glucose at both previous examinations (persistent impaired fasting glucose) was 30.4% (222/1518) compared with 0.6% (15/5063) of those with normal fasting glucose at both baseline and initial follow-up. The hazard ratios to develop diabetes, adjusted for possible confounders, was 37.10 (95% CI, 21.6-63.7) for persistent impaired fasting glucose versus persistent normal fasting glucose. Persistent impaired fasting glucose predicted diabetes at 80.7% (222/275) sensitivity and 83.1% (6358/7654) specificity, whereas first baseline impaired fasting glucose only predicted diabetes at 86.9% (239/275) sensitivity and 74.9% (5730/7654) specificity. The model using both previous fasting plasma glucose levels had a greater AUROC (area under receiver operating characteristic) than that using first baseline fasting plasma glucose only (0.92 vs. 0.88; P < 0.001).
CONCLUSIONS: Repeated measurements of fasting plasma glucose better predicts incidence of diabetes than a single test. In particular, persistent fasting hyperglycaemia adds more substantial precision to the prediction of future diabetes than transient impaired fasting glucose. This combination is cost efficient and may be practical for early detection of high-risk individuals.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22150345     DOI: 10.1111/j.1464-5491.2011.03536.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

1.  Discordance in glycemic categories and regression to normality at baseline in 10,000 people in a Type 2 diabetes prevention trial.

Authors:  Mike Sampson; Tim Elwell-Sutton; Max O Bachmann; Allan Clark; Ketan K Dhatariya; Clare Ferns; Amanda Howe; W Garry John; Gerry Rayman; Leyla Swafe; Jeremy Turner; Melanie Pascale
Journal:  Sci Rep       Date:  2018-04-19       Impact factor: 4.379

2.  Effects of multi-metal exposure on the risk of diabetes mellitus among people aged 40-75 years in rural areas in southwest China.

Authors:  Jing Zhang; Huanhuan Yin; Xuemei Zhu; Rong Xiang; Yeqiu Miao; Yu Zhang; Yang Song; Jinyao Chen; Lishi Zhang
Journal:  J Diabetes Investig       Date:  2022-04-04       Impact factor: 3.681

3.  Concordance of two diabetes diagnostic criteria using fasting plasma glucose and hemoglobin A1c: the Yuport Medical Checkup Centre study.

Authors:  Kazuo Inoue; Saori Kashima; Chisako Ohara; Masatoshi Matsumoto; Kimihiko Akimoto
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

4.  Do non-glycaemic markers add value to plasma glucose and hemoglobin a1c in predicting diabetes? Yuport health checkup center study.

Authors:  Saori Kashima; Kazuo Inoue; Masatoshi Matsumoto; Kimihiko Akimoto
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

5.  Effects of age and sex in the diagnosis of type 2 diabetes using glycated haemoglobin in Japan: the Yuport Medical Checkup Centre study.

Authors:  Machiko Inoue; Kazuo Inoue; Kimihiko Akimoto
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.